European Union - English - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - acute coronary syndromemyocardial infarction

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - sildenafil base (as citrate) - film coated tablet - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - sildenafil base (as citrate) - film coated tablet - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - sildenafil base (as citrate) - film coated tablet - 25 milligram

Israel - English - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - English - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - English - Ministry of Health

sanofi israel ltd - sarilumab - solution for injection - sarilumab 131.6 mg / 1 ml - sarilumab - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.

Israel - English - Ministry of Health

sanofi israel ltd - sarilumab - solution for injection - sarilumab 175 mg / 1 ml - sarilumab - kevzara in combination with methotrexate (mtx) is indicated for the treatment of moderately to severely active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). kevzara can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate.kevzara is indicated for treatment of adult patients with polymyalgia rheumatica who cannot tolerate corticosteroid taper

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - dronedarone hydrochloride 426mg eqv dronedarone - tablet, film coated - 400 mg - dronedarone hydrochloride 426mg eqv dronedarone 400 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aflibercept -